Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ProPhase Labs stock

Own ProPhase Labs stock in just a few minutes.

ProPhase Labs, Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 95 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ProPhase Labs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ProPhase Labs share price

Use our graph to track the performance of PRPH stocks over time.

ProPhase Labs shares at a glance

Information last updated 2021-04-23.
52-week range$1.37 - $16.04
50-day moving average $6.26
200-day moving average $8.65
Wall St. target price$22.50
PE ratio N/A
Dividend yield N/A (13.16%)
Earnings per share (TTM) $-0.33

Buy ProPhase Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ProPhase Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProPhase Labs financials

Revenue TTM $14.5 million
Gross profit TTM $4.6 million
Return on assets TTM -11.4%
Return on equity TTM -21.35%
Profit margin -14.64%
Book value $0.91
Market capitalisation $76.7 million

TTM: trailing 12 months

Shorting ProPhase Labs shares

There are currently 174,331 ProPhase Labs shares held short by investors – that's known as ProPhase Labs's "short interest". This figure is 42.8% up from 122,068 last month.

There are a few different ways that this level of interest in shorting ProPhase Labs shares can be evaluated.

ProPhase Labs's "short interest ratio" (SIR)

ProPhase Labs's "short interest ratio" (SIR) is the quantity of ProPhase Labs shares currently shorted divided by the average quantity of ProPhase Labs shares traded daily (recently around 484252.77777778). ProPhase Labs's SIR currently stands at 0.36. In other words for every 100,000 ProPhase Labs shares traded daily on the market, roughly 360 shares are currently held short.

However ProPhase Labs's short interest can also be evaluated against the total number of ProPhase Labs shares, or, against the total number of tradable ProPhase Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProPhase Labs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ProPhase Labs shares in existence, roughly 10 shares are currently held short) or 0.0141% of the tradable shares (for every 100,000 tradable ProPhase Labs shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProPhase Labs.

Find out more about how you can short ProPhase Labs stock.

ProPhase Labs share dividends

We're not expecting ProPhase Labs to pay a dividend over the next 12 months.

Have ProPhase Labs's shares ever split?

ProPhase Labs's shares were split on a 2:1 basis on 22 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.

ProPhase Labs share price volatility

Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $1.37 up to $16.04. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is -0.0678. This would suggest that ProPhase Labs's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ProPhase Labs has bucked the trend.

ProPhase Labs overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site